Drug Profile
OM MUC 1
Alternative Names: Oxidised-mannan MUC1 vaccineLatest Information Update: 05 Sep 2018
Price :
$50
*
At a glance
- Originator Austin Research Institute
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 05 Sep 2018 Discontinued - Phase-I/II for Breast cancer (Prevention) in Australia (Parenteral)
- 05 Sep 2018 Discontinued - Phase-II/III for Breast cancer (Early-stage disease, Prevention, Second-line therapy or greater, Adjuvant therapy) in Greece (Parenteral)
- 10 Oct 2015 Efficacy, immunogenicity and adverse events data from the phase IIb/III IFCM-9 trial in Breast cancer (Adjuvant therapy, Early-stage disease, Second-line therapy or greater, Prevention) released by Ascend Biopharmaceuticals (3151181; ISRCTN71711835)